Payment overview · 2025
General Payments
$740.10
38 reported records · 19 companies
Healthcare provider profile · identity verified
Michael P Harris, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEST COLUMBIA, SC · NPI 1376551903
Verified facts
What the public records show
CMS Open Payments records show Michael P Harris, MD received $740.10 in general payments during 2025 across 38 reported records.
Dexcom, Inc. accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $96.26 | 13.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.62 | 12.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.66 | 10.4% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.67 | 9.0% | 3 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $50.91 | 6.9% | 2 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $40.39 | 5.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.15 | 4.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.68 | 4.4% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $31.36 | 4.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.41 | 4.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.69 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.41 | 4.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.51 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.31 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.68 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.57 | 2.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.23 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.03 | 2.0% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $13.56 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $740.10 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $96.26 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $66.67 | 3 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $50.91 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.32 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.30 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $44.44 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $44.15 | 3 | 2025 |
Source payment records
|
|||||
| ROSA Normalized: rosa |
Device | Zimmer Biomet Holdings, Inc. | $40.39 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $31.36 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.41 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.69 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 86 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 552 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 321 | 89 |
| Omeprazole | Omeprazole | 300 | 88 |
| Meloxicam | Meloxicam | 238 | 85 |
| Losartan Potassium | Losartan Potassium | 218 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 68 |
| Lisinopril | Lisinopril | 183 | 50 |
| Metformin Hcl | Metformin Hcl | 183 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 48 |
| Tramadol Hcl | Tramadol Hcl | 162 | 45 |
| Alprazolam | Alprazolam | 155 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 28 |
| Lorazepam | Lorazepam | 141 | 27 |
| Gabapentin | Gabapentin | 137 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 29 |
| Diclofenac Sodium Er | Diclofenac Sodium | 134 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 133 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 34 |
| Temazepam | Temazepam | 128 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 31 |
| Famotidine | Famotidine | 109 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 103 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 31 |
| Januvia | Sitagliptin Phosphate | 94 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 25 |
| Ozempic | Semaglutide | 89 | 23 |
| Bupropion Xl | Bupropion Hcl | 87 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 37 |
| Farxiga | Dapagliflozin Propanediol | 86 | 24 |
| Allopurinol | Allopurinol | 85 | 27 |
| Metformin Hcl Er | Metformin Hcl | 83 | 22 |
| Anastrozole | Anastrozole | 80 | 23 |
| Celecoxib | Celecoxib | 75 | 22 |
| Furosemide | Furosemide | 70 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 23 |
| Jardiance | Empagliflozin | 67 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 19 |
| Simvastatin | Simvastatin | 64 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 23 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Prednisone | Prednisone | 54 | 42 |
| Trazodone Hcl | Trazodone Hcl | 54 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 17 |
| Estradiol | Estradiol | 53 | 17 |
| Montelukast Sodium | Montelukast Sodium | 52 | 19 |
| Diazepam | Diazepam | 51 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 45 |
| Azithromycin | Azithromycin | 46 | 43 |
| Potassium Chloride | Potassium Chloride | 45 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 12 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Progesterone | Progesterone, Micronized | 42 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 23 |
| Carvedilol | Carvedilol | 39 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Pregabalin | Pregabalin | 38 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 30 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 14 |
| Glimepiride | Glimepiride | 34 | 12 |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Eliquis | Apixaban | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 19 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 13 |
| Testosterone | Testosterone | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $740.10 · 38 records | Dexcom, Inc. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Heplisav-B, INJECTAFER, INSPIRE, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, ROSA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, Wegovy, XYOSTED | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error